Publications by authors named "S A Gilmore"
Objectives: Hydrazine (HZ) and Hydrazine Derivative (HZ-D) exposures pose health risks to people in industrial and aerospace settings. Several recent systematic reviews and case series have highlighted common clinical presentations and management strategies. Given the low frequency at which HZ and HZ-D exposures occur, a strong evidence base on which to develop an evidence-based guideline does not exist at this time.
View Article and Find Full Text PDFArticle Synopsis
- - The SingWell Project aims to investigate whether group singing can improve speech-in-noise perception and overall mental health in older adults experiencing unaddressed hearing loss, addressing gaps in previous studies.
- - The study will involve 210 participants aged 60 and above, who will be randomly assigned to either a group singing program or an audiobook club for 12 weeks, with various assessments conducted throughout.
- - Researchers anticipate that engaging in group singing will significantly enhance both communication abilities in noisy environments and participants' psychosocial wellbeing.
Article Synopsis
- - Chlamydia is a widespread bacterial STD that often goes unnoticed, creating a need for a preventive vaccine to address its serious health risks.
- - Cell-free protein synthesis (CFPS) allows for quick and adaptable production of vaccine proteins, demonstrated by producing the chlamydial CT584 protein for testing in mice.
- - Although CT584 prompted strong antibody responses, it failed to effectively protect against chlamydia infection, highlighting CFPS's potential for producing other antigens even if this candidate wasn't successful.
There is broad consensus that listening effort is an important outcome for measuring hearing performance. However, there remains debate on the best ways to measure listening effort. This study sought to measure neural correlates of listening effort using functional near-infrared spectroscopy (fNIRS) in experienced adult hearing aid users.
View Article and Find Full Text PDFArticle Synopsis
- Severe tricuspid regurgitation is often inadequately treated due to a lack of effective options, but transcatheter tricuspid valve interventions are gaining attention as a potential solution.
- The TRISCEND II pivotal trial is the first randomized controlled trial to assess the safety and effectiveness of the EVOQUE transcatheter tricuspid valve replacement system, which received FDA Breakthrough Device Designation.
- This trial has a unique two-phase design that allows for early analysis of patient outcomes, helping to set a standard for future research in transcatheter valve devices.